Focused on creating the next frontier of surgery, New Brunswick-based Johnson & Johnson (J&J) announced that its Ethicon, Inc. division has entered into a definitive agreement to acquire Auris Health, Inc. for approximately $3.4 billion in cash. Auris Health is a privately held developer of robotic technologies, initially focused in lung cancer. This acquisition will accelerate J&J’s entry into robotics with potential for growth and expansion into other interventional applications.
“In this new era of healthcare, we’re aiming to simplify surgery, drive efficiency, reduce complications and improve outcomes for patients, ultimately making surgery safer,” said Ashley McEvoy, executive vice president, worldwide chairman, medical devices, J&J. “We believe the combination of best-in-class robotics, advanced instrumentation and unparalleled end-to-end connectivity will make a meaningful difference in patient outcomes.”
With this acquisition, Frederic Moll, M.D., CEO and founder of Auris Health, will be joining J&J upon completion of this transaction.
“We’re thrilled to be joining J&J to help push the boundaries of what is possible in medical robotics and improve the lives of patients across the globe. Together, we will be able to dramatically accelerate our collective product innovation to develop new interventional solutions that redefine optimal patient outcomes,” said Dr. Moll. “This combination is a testament to the incredible work of the Auris Health team and the innovation engine behind the Monarch Platform, which represents a huge step forward in endoluminal technology. We look forward to continuing to shape the future of intervention with the added expertise and resources of the world’s largest healthcare organization.”
To access more business news, visit NJB News Now.Related Articles: